.jpg "Dermata Therapeutics (NASDAQ: DRMA)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dermata Therapeutics (DRMA – Research Report) and Boston Scientific (BSX – Research Report).
Dermata Therapeutics (DRMA)
Brookline Capital Markets analyst Kumaraguru Raja initiated coverage with a Buy rating on Dermata Therapeutics today and set a price target of $14.00. The company’s shares closed last Tuesday at $5.16.
According to TipRanks.com, Raja is a 4-star analyst with an average return of
Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.50, implying a 143.1% upside from current levels. In a report issued on September 14, Maxim Group also initiated coverage with a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
Boston Scientific (BSX)
Needham analyst Michael Matson maintained a Hold rating on Boston Scientific today. The company’s shares closed last Tuesday at $43.89.
According to TipRanks.com, Matson is a 5-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $59.85, implying a 36.0% upside from current levels. In a report issued on September 17, Leerink Partners also maintained a Hold rating on the stock with a $48.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DRMA:
